Learning Objectives:

1. Discuss monotherapy in renal cell carcinoma and the preclinical evidence for combining antiangiogenic agents and immunotherapy. 

2. Examine the current data on combination antiangiogenic agents and immunotherapy. 

3. Learn about upcoming trials involving combination therapy 

Session date: 
07/02/2018 - 12:00pm to 1:00pm CDT
5841 South Maryland Avenue
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Brian Heiss, MD